SARS-CoV-2 mAb Program
COVID-19
Pre-clinicalActive
Key Facts
About Adnexus
Adnexus is a private, pre-revenue biotech company pioneering an AI-driven approach to monoclonal antibody discovery against infectious diseases. Its core technology, the Sutra™ platform, analyzes viral targets to identify immutable epitopes and facilitates rapid antibody generation from human B-cells of recovered patients. The company has demonstrated proof-of-concept by identifying conserved targets for HIV, SARS-CoV-2, and Monkeypox, positioning itself in the high-need market for broad-spectrum antiviral therapeutics.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |